142 related articles for article (PubMed ID: 34185077)
1. Tocilizumab, blood cells, and mild COVID-19: delayed vascular protection by interleukin blockade?
Buryachkovskaya L; Lomakin N; Melkumyants A; Docenko J; Serebruany V
Eur Heart J Cardiovasc Pharmacother; 2021 Sep; 7(5):e81-e82. PubMed ID: 34185077
[No Abstract] [Full Text] [Related]
2. Tocilizumab for treatment patients with COVID-19: Recommended medication for novel disease.
Samaee H; Mohsenzadegan M; Ala S; Maroufi SS; Moradimajd P
Int Immunopharmacol; 2020 Dec; 89(Pt A):107018. PubMed ID: 33045577
[TBL] [Abstract][Full Text] [Related]
3. Preemptive interleukin-6 blockade in patients with COVID-19.
Guillén L; Padilla S; Fernández M; Agulló V; García JA; Telenti G; García-Abellán J; Botella Á; Gutiérrez F; Masiá M
Sci Rep; 2020 Oct; 10(1):16826. PubMed ID: 33033405
[TBL] [Abstract][Full Text] [Related]
4. Rapid radiological improvement of COVID-19 pneumonia after treatment with tocilizumab.
Comel AC; Mosaner W; Bragantini D; Lanzafame M
Infection; 2021 Feb; 49(1):195-196. PubMed ID: 32557206
[No Abstract] [Full Text] [Related]
5. Audio Interview: A New SARS-CoV-2 Vaccine and a New Look at Treatment.
Rubin EJ; Baden LR; Morrissey S
N Engl J Med; 2021 Mar; 384(9):e46. PubMed ID: 33657301
[No Abstract] [Full Text] [Related]
6. Treat 2019 novel coronavirus (COVID-19) with IL-6 inhibitor: Are we already that far?
Zhang Y; Zhong Y; Pan L; Dong J
Drug Discov Ther; 2020; 14(2):100-102. PubMed ID: 32378647
[TBL] [Abstract][Full Text] [Related]
7. Effects of Tocilizumab in COVID-19 patients: a cohort study.
Vu CA; DeRonde KJ; Vega AD; Maxam M; Holt G; Natori Y; Zamora JG; Salazar V; Boatwright R; Morris SR; de Lima Corvino D; Betances AF; Colucci L; Keegan J; Lopez A; Rezk AH; Rodriguez Y; Moraru GM; Doblecki S; De La Zerda DJ; Abbo LM
BMC Infect Dis; 2020 Dec; 20(1):964. PubMed ID: 33353546
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-6 receptor antagonist therapy to treat SARS-CoV-2 driven inflammatory syndrome in a kidney transplant recipient.
Allam SR; Dao A; Madhrira MM; Antiporta PB; Nair RR; Guiteau JJ; Reyad AI
Transpl Infect Dis; 2020 Aug; 22(4):e13326. PubMed ID: 32406985
[No Abstract] [Full Text] [Related]
9. Is IL-6 a key cytokine target for therapy in COVID-19?
Jones SA; Hunter CA
Nat Rev Immunol; 2021 Jun; 21(6):337-339. PubMed ID: 33850327
[TBL] [Abstract][Full Text] [Related]
10. Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial.
Maes B; Bosteels C; De Leeuw E; Declercq J; Van Damme K; Delporte A; Demeyere B; Vermeersch S; Vuylsteke M; Willaert J; Bollé L; Vanbiervliet Y; Decuypere J; Libeer F; Vandecasteele S; Peene I; Lambrecht B
Trials; 2020 Jun; 21(1):468. PubMed ID: 32493441
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-6 receptor blockade with subcutaneous tocilizumab improves coagulation activity in patients with COVID-19.
Di Nisio M; Potere N; Candeloro M; Spacone A; Pieramati L; Ferrandu G; Rizzo G; La Vella M; Di Carlo S; Cibelli D; Parruti G; Levi M; Porreca E
Eur J Intern Med; 2021 Jan; 83():34-38. PubMed ID: 33162299
[TBL] [Abstract][Full Text] [Related]
12. Tocilizumab: A Therapeutic Option for the Treatment of Cytokine Storm Syndrome in COVID-19.
Saha A; Sharma AR; Bhattacharya M; Sharma G; Lee SS; Chakraborty C
Arch Med Res; 2020 Aug; 51(6):595-597. PubMed ID: 32482373
[TBL] [Abstract][Full Text] [Related]
13. Tocilizumab in Hospitalized Patients with COVID-19: A Meta Analysis of Randomized Controlled Trials.
Selvaraj V; Khan MS; Bavishi C; Dapaah-Afriyie K; Finn A; Lal A; Mylonakis E
Lung; 2021 Jun; 199(3):239-248. PubMed ID: 34050796
[TBL] [Abstract][Full Text] [Related]
14. Tocilizumab for the Treatment of COVID-19-Induced Cytokine Storm and Acute Respiratory Distress Syndrome: A Case Series From a Rural Level 1 Trauma Center in Western Pennsylvania.
Suresh K; Figart M; Formeck S; Mehmood T; Abdel Salam M; Bassilly D
J Investig Med High Impact Case Rep; 2021; 9():23247096211019557. PubMed ID: 34105382
[TBL] [Abstract][Full Text] [Related]
15. Tocilizumab combined with favipiravir in the treatment of COVID-19: A multicenter trial in a small sample size.
Zhao H; Zhu Q; Zhang C; Li J; Wei M; Qin Y; Chen G; Wang K; Yu J; Wu Z; Chen X; Wang G
Biomed Pharmacother; 2021 Jan; 133():110825. PubMed ID: 33378989
[TBL] [Abstract][Full Text] [Related]
16. Anti-IL-6 receptor antibody treatment for severe COVID-19 and the potential implication of IL-6 gene polymorphisms in novel coronavirus pneumonia.
Ulhaq ZS; Soraya GV
Med Clin (Barc); 2020 Dec; 155(12):548-556. PubMed ID: 32950258
[No Abstract] [Full Text] [Related]
17. The Role of Tocilizumab in Cytokine Storm and Improving Outcomes in COVID-19.
Ali A; Kamjani MH; Kesselman MM
Recent Pat Antiinfect Drug Discov; 2020; 15(2):104-112. PubMed ID: 32962623
[TBL] [Abstract][Full Text] [Related]
18. Pulmonary vascular improvement in severe COVID-19 patients treated with tocilizumab.
Salvati L; Occhipinti M; Gori L; Ciani L; Mazzoni A; Maggi L; Capone M; Parronchi P; Liotta F; Miele V; Annunziato F; Lavorini F; Cosmi L
Immunol Lett; 2020 Dec; 228():122-128. PubMed ID: 33161002
[TBL] [Abstract][Full Text] [Related]
19. Tocilizumab for Severe Worsening COVID-19 Pneumonia: a Propensity Score Analysis.
Roumier M; Paule R; Vallée A; Rohmer J; Ballester M; Brun AL; Cerf C; Chabi ML; Chinet T; Colombier MA; Farfour E; Fourn E; Géri G; Khau D; Marroun I; Ponsoye M; Roux A; Salvator H; Schoindre Y; Si Larbi AG; Tchérakian C; Vasse M; Verrat A; Zuber B; Couderc LJ; Kahn JE; Groh M; Ackermann F;
J Clin Immunol; 2021 Feb; 41(2):303-314. PubMed ID: 33188624
[TBL] [Abstract][Full Text] [Related]
20. Invasive pulmonary aspergillosis after treatment with tocilizumab in a patient with COVID-19 ARDS: a case report.
Witting C; Quaggin-Smith J; Mylvaganam R; Peigh G; Angarone M; Flaherty JD
Diagn Microbiol Infect Dis; 2021 Apr; 99(4):115272. PubMed ID: 33388572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
